Pediatrix Medical Group, Inc. (NYSE:MD) is one of the On May 5, 2026, Pediatrix Medical Group, Inc. (NYSE:MD) reported Q1 adjusted EPS of 44c, versus the consensus estimate of 38c.
Revenue totaled $476M, versus the consensus estimate of $465.82M
Same-unit revenue from net reimbursement-related factors increased 4.4% year over year. CEO Mark Ordan said first-quarter operating results exceeded expectations, driven by top-line growth, while adding that the company’s priorities for 2026 remain centered on supporting hospital partners through quality-focused care delivery. Ordan also said Pediatrix believes its strong cash flow generation and balance sheet position the company to pursue additional opportunities moving forward.
Pediatrix Medical Group, Inc. (NYSE:MD) reaffirmed its FY26 adjusted EBITDA outlook of $280M-$300M. On April 20, 2026, Jefferies analyst Jack Slevin raised the firm’s price target on Pediatrix Medical Group, Inc. (NYSE:MD) to $27 from $24 while maintaining a Buy rating. The firm said recent underperformance across healthcare services stocks reflected investor concerns tied to Q1 patient volumes, though Jefferies questioned whether consensus expectations fully accounted for weather-related disruptions caused by winter storms in Southern and East Coast markets.